A drug-resistant fatal superbug fungus is developing in various countries across the world. The Centers for Disease Control and Prevention says those superbugs can kill people within around three months. Even more, reports from the CDC reveals there are 587 confirmed cases of the fatal infection in the U.S. Thus emerging global cases of Candida auris, a disease, has become a critical risk. Experts say the fungus is rapidly surfacing as a global threat, as it is liable for a number of deaths around the worldwide. Researchers worry about the fungus’ resistance to significant treatments and infection of at-risk groups.
C. auris is a species of fungus discovered in 2009, which has spread through minimum 15 countries. It also resulted in fatal outcomes. The fungus can remain for a long time on human skin as well as on objects. It may exist on hospital furniture, apparatus, or other places for a long period of time. Thus, the fatal infection can circulate from one person to another. It is a powerful bug as it is resistant to the three major categories of anti-fungal medicines. So doctors have very few alternatives to treat the infection caused by C. auris.
A study published, last year, in the journal Emerging Infectious Diseases reveals how dangerous the infection can be. The research analyzed 51 cases of C. auris infections that took place in New York City between 2016-2018. Among those, nearly half of the patients died within 90 days after the diagnosis of C. auris. Even more, fluconazole, a common anti-fungal drug, did not have any impact on all samples of the fungus. Experts say the yeast targets people with lower immunity, like infants and older adults. Even after the death of the infected person, the fungus remains active and continues to reproduce. Notably, it takes home in hospital rooms and raises in people who are already sick. Besides, the symptoms of fungal infection are difficult to detect. Although, it is challenging to treat these fatal drug-resistant infections.